KCNA3 and nervous system disorder: GFP–MgTx can be used as a component of an analytical system based on the hybrid KcsA–Kv1.3 channel for screening, assessment of affinity and pre-selection of Kv1.3 blockers for their subsequent study as potential drugs for the treatment of autoimmune and neurological disorders.